2024-10-29 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**1. Performance Comparison:**

Abbott Laboratories (ABT) is a healthcare company that develops, manufactures, and markets a wide range of pharmaceutical, diagnostic, nutritional, and medical device products. 

As of the last data point, ABT's cumulative return is 104.23%, lagging behind the S&P 500 (VOO) which has a cumulative return of 136.36%.  This represents a **-32.13%** difference. The relative divergence indicates that ABT is currently performing **11.06%** below the average divergence between its historical performance and the S&P 500.

**2. Recent Price Movement:**

* **Closing Price:** $114.07 (Last-market: $114.13)
* **5-day Moving Average:** $115.59
* **20-day Moving Average:** $115.56
* **60-day Moving Average:** $113.78

The current price is slightly below the 5-day and 20-day moving averages, suggesting a potential short-term downward trend. However, the 60-day moving average is lower, implying that the stock might be in a consolidation phase.

**3. Technical Indicators Analysis:**

* **RSI:** 48.12: This indicates that the stock is currently in a neutral territory, neither overbought nor oversold.
* **PPO:** -0.28: This negative value suggests a potential bearish trend, indicating that the stock's price momentum is weakening.
* **Delta_Previous_Relative_Divergence:** -1.97: This indicates a short-term decline in the stock's relative performance.
* **Expected Return:** 0.0%: This indicates that ABT is expected to deliver a 0% return in the long-term (2+ years) compared to the S&P 500. 

**4. Recent Earnings and Outlook:**

| Date          | EPS  | Revenue        |
|---------------|------|-----------------|
| 2024-07-31 | 0.74 | $10.38 B$       |
| 2024-05-02 | 0.70 | $9.96 B$        |
| 2023-11-01 | 0.82 | $10.14 B$       |
| 2023-08-03 | 0.79 | $9.98 B$        |
| 2024-07-31 | 0.79 | $9.98 B$        |

The latest earnings report shows that ABT has consistently generated strong revenue and EPS. However, the company has been struggling to beat analysts' estimates in recent quarters. 

**5. Financial Trends Analysis:**

| Item               | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|--------------------|---------------|---------------|---------------|
| Revenue            | $10.38B         | $9.96B          | $10.24B         | 
| Gross Profit       | $5.77B          | $5.50B          | $5.68B          | 
| Gross Margin %     | 55.64%          | 55.21%          | 55.51%          | 
| Operating Income   | $1.67B          | $1.39B          | $1.78B          | 
| Operating Margin % | 16.08%          | 13.91%          | 17.38%          | 
| Net Income         | $1.30B          | $1.23B          | $1.59B          | 
| Net Margin %       | 12.55%          | 12.29%          | 15.56%          | 
| EPS                | $0.75           | $0.70           | $0.92           | 
| ROE %              | 3.31%           | 3.16%           | 4.13%           | 
| Total Assets       | $73.02B         | $72.47B         | $73.21B         | 
| Total Liabilities  | $33.46B         | $33.42B         | $34.39B         | 
| Total Equity       | $39.32B         | $38.81B         | $38.60B         | 
| Operating Cash Flow | $1.96B          | $1.02B          | $3.04B          | 
| Capital Expenditure | $-0.53B         | $-0.40B         | $-0.76B         | 

The company shows a steady revenue growth and maintained consistent profit margins. The operating cash flow is also strong, indicating solid profitability. 

**6. News and Recent Events:**

**Earnings News (Recent 2 Days):**

[You will need to access a financial news website or platform to check for recent earnings announcements specific to ABT. Shacknews is a good option for recent market news.]

**Recent Market Outlook:** 

[You will need to research ABT on FINBOLD or other reputable finance websites to understand the current market outlook, analyst opinions, and performance highlights.]

**7.  Overall Analysis:**

Abbott Laboratories is a well-established healthcare company with a diverse product portfolio. It has a strong financial position and consistent revenue growth. However, its recent performance has lagged behind the broader market, and its technical indicators suggest potential weakness. While the company is facing some headwinds, its long-term prospects remain positive given its strong brand recognition, extensive product offerings, and robust financial performance.

**8. Conclusion:**

ABT is a solid company, but its recent performance has been underwhelming. It is essential to carefully consider its current market conditions, technical indicators, and analyst opinions before making any investment decisions.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. 
